Provided by Tiger Fintech (Singapore) Pte. Ltd.

MoonLake Immunotherapeutics

41.44
-0.6400-1.52%
Post-market: 41.440.00000.00%16:05 EDT
Volume:359.45K
Turnover:14.86M
Market Cap:2.62B
PE:-21.91
High:42.00
Open:41.91
Low:40.33
Close:42.08
Loading ...

MoonLake Immunotherapeutics - Phase 2 and 3 Data Read-Outs Expected in 2025 and 2026

THOMSON REUTERS
·
08 Jan

MoonLake Immunotherapeutics - Primary Endpoint of S-Olaris Trial Is Change in 18F-Naf Uptake

THOMSON REUTERS
·
08 Jan

MoonLake Immunotherapeutics - Running Seven Trials in 2025

THOMSON REUTERS
·
08 Jan

MoonLake Initiates Three New Clinical Trials and Further Expands the Portfolio of Indications for the Nanobody® Sonelokimab

THOMSON REUTERS
·
08 Jan

MoonLake Immunotherapeutics Announces Board Changes and Incentives

TIPRANKS
·
19 Dec 2024

Stifel Nicolaus Sticks to Its Buy Rating for MoonLake Immunotherapeutics (MLTX)

TIPRANKS
·
17 Dec 2024

Oppenheimer Keeps Their Buy Rating on MoonLake Immunotherapeutics (MLTX)

TIPRANKS
·
11 Dec 2024

MoonLake Immunotherapeutics’ Promising SLK Therapy Forecasts Strong Market Performance and Stock Potential

TIPRANKS
·
21 Nov 2024

MoonLake Immunotherapeutics management to meet with Oppenheimer

TIPRANKS
·
18 Nov 2024

MoonLake Immunotherapeutics’ Promising Phase 3 Trials for PsA Treatment Drives Buy Rating

TIPRANKS
·
14 Nov 2024

Oppenheimer Reaffirms Their Buy Rating on MoonLake Immunotherapeutics (MLTX)

TIPRANKS
·
14 Nov 2024

MoonLake Immunotherap Price Target Maintained With a $100.00/Share by HC Wainwright & Co.

Dow Jones
·
14 Nov 2024

BRIEF-Moonlake Immunotherapeutics Topline Primary Endpoint Readout At Week 16 For Phase 3 IZAR Program Expected In H1 2026

Reuters
·
13 Nov 2024

MoonLake Immunotherapeutics: Topline Primary Endpoint Readout at Week 16 for Phase 3 Izar Program Expected in H1 2026

THOMSON REUTERS
·
13 Nov 2024

MoonLake Immunotherapeutics Starts Phase 3 Izar Program of the Nanobody® Sonelokimab in Patients With Active Psoriatic Arthritis

THOMSON REUTERS
·
13 Nov 2024

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis

GlobeNewswire
·
13 Nov 2024

Buy Rating for MoonLake Immunotherapeutics Driven by Clinical Advancements and Market Opportunities

TIPRANKS
·
11 Nov 2024

MoonLake Immunotherapeutics Reports Q3 2024 Financial Results

TIPRANKS
·
09 Nov 2024

MoonLake Immunotherap Price Target Maintained With a $100.00/Share by HC Wainwright & Co.

Dow Jones
·
09 Nov 2024

Analysts Conflicted on These Healthcare Names: Molina Healthcare (MOH), Avidity Biosciences (RNA) and MoonLake Immunotherapeutics (MLTX)

TIPRANKS
·
08 Nov 2024